Catalyst Pharmaceuticals Reports Solid First Quarter 2024 Financial Results and Provides Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Catalyst Pharmaceuticals (CPRX) Tops Q1 EPS by 16c, Misses on Revenue; Offers FY24 Revenue Guidance
May 8, 2024 4:44 PM EDTCatalyst Pharmaceuticals (NASDAQ: CPRX) reported Q1 EPS of $0.38, $0.16 better than the analyst estimate of $0.22. Revenue for the quarter came in at $98.44 million versus the consensus estimate of $99.03 million.
GUIDANCE:
Catalyst Pharmaceuticals sees FY2024 revenue of $455-475 million, versus the consensus of... More
